trial

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

NCTId NCT06276361
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 58 (actual)
Sponsored by Rovi Pharmaceuticals Laboratories
Primary completion 2025-07-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
58 (actual)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
None
Start
2023-09-26
Primary completion
2025-07-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Rovi Pharmaceuticals LaboratoriesLead Sponsor

Sites

1 total
Amman, Jordan

Facts & assertions

4 sourced
Enrollment
58
Phase
PHASE1
Primary Completion Date
2025-07-07
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Rovi Pharmaceuticals Laboratories
company
indication
Schizophrenia
indication
Schizophrenia
indication